In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: QuidelOrtho’s current price at $14.36 is significantly below the PERT-weighted fair value of $21.46, indicating a 49.4% implied upside supported by diverse valuation methods except for the negative DCF results. Financial health scores reveal poor profitability and efficiency, suggesting operational challenges despite moderate liquidity. Monte Carlo analysis shows no downside risk below current price, reflecting limited immediate valuation risk.